June 29, 2020
Cancer Screening Programs Influence Incidence and Causes of Cancer DeathsBookmarkLola Rahib, PhD
Article from ASCO Daily News curated by Director of Scientific and Clinical Affairs, Lola Rahib, PhD.
In collaboration with MD Anderson Cancer Center and the Pancreatic Cancer Action Network, Cancer Commons presented new research at the American Society of Clinical Oncology (ASCO)’s virtual 2020 meeting. The findings show that, by 2040, we will likely see notable changes in which cancer types are most common and which are most deadly, highlighting the influence of cancer screening programs. This research was led by Dr. Rahib at Cancer Commons.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
May 20, 2020 Lola Rahib, PhD
The ongoing COVID-19 pandemic presents unprecedented challenges to cancer patients. Many have experienced changes to their care, and some face increased risk of infection or worse prognosis if they are… Read more »
May 12, 2020 Lola Rahib, PhD
The American Cancer Society estimates that in 2020, 57,600 people in the U.S. will be diagnosed with pancreatic cancer and 47,050 will die from the disease. But not everyone’s pancreatic… Read more »
January 10, 2020
Using Real World Evidence to Show Initial Results of a Drug Combination in Pancreatic Cancer PatientsLola Rahib, PhD
In collaboration with xCures and the Huntsman Cancer Institute at the University of Utah, Cancer Commons presented initial findings from our real-world data registry on a novel treatment combination for… Read more »
August 5, 2019 Lola Rahib, PhD
A Q&A with Lola Rahib, PhD, Lead Scientist, Pancreas Cancer, at Cancer Commons, Los Altos, CA; firstname.lastname@example.org Q: Navigating a pancreatic cancer diagnosis can be overwhelming and confusing for patients… Read more »